Skip to main content
Premium Trial:

Request an Annual Quote

Pall to Acquire ForteBio

NEW YORK (GenomeWeb News) – Pall today said that it has signed an agreement to acquire protein analysis products firm ForteBio for an undisclosed sum.

Menlo Park, Calif.-based ForteBio makes label-free protein analysis instruments that are expected to complement Pall's existing portfolio of microbiological monitoring platforms. The privately held firm's primary platform is its Octet family of products, which enables the measurement of multiple interactions in parallel without the use of detection agents. ForteBio also recently launched its BLItz platform for single-sample analysis.

Port Washington, NY-based Pall said that the acquisition will extend its capabilities in the "more than $1 billion" biopharmaceuticals process monitoring market, as well as the protein research field.

"Pall's strong global sales channel will extend the reach of ForteBio instruments and better position us to capitalize on opportunities in emerging regions in Europe and Asia," Joseph Keegan, ForteBio CEO and president, said in a statement. "Demand for label-free protein analysis continues to intensify and through the merger we now can bring the advantages of ForteBio systems to a wider range of customers."

The firms expect to complete the deal by February 2012. After the close of the transaction, ForteBio will operate as a wholly-owned subsidiary of Pall.